Sentinox (STX)-005: a next-generation therapy for autoimmune disease to sustain force readiness

Active Purchase Order Awarded Last action

Contract number
FA864925P0501
Awardee
Awarding agency
Obligated
$1,249,609

Award facts

Contract value 100% obligated
$1,249,609.00 Current and potential, with all options
Completion date 65% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 87 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Boston, MA 02215, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00001 $0
Original award $1,249,609

About this award

The Air Force Research Laboratory awarded a purchase order to Strand Therapeutics Inc. for $1,249,609 on August 29, 2025, under a total small business set-aside. The order funds development of SENTINOX (STX)-005, a next-generation therapy for autoimmune disease to sustain force readiness. Work is performed in Boston, Massachusetts, with ultimate completion by May 31, 2027. Pricing is firm fixed price.

Quick answers

Who was awarded contract FA864925P0501?

FA864925P0501 was awarded to Strand Therapeutics Inc. by Air Force Research Laboratory (Air Force Materiel Command) on August 29, 2025.

How much is contract FA864925P0501 worth?

The government has obligated $1,249,609 on FA864925P0501.

Was contract FA864925P0501 competed?

The extent of competition for FA864925P0501 was full and open competition after exclusion of sources. The government received 87 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award